Dear all,
I am wondering if anyone has a specific policy in place at their institution which addresses opening dofetilide (Tikosyn) capsules for oral administration. It seems to be a bit of a gray area. ISMP has not addressed this to date and the manufacturer offers no clear guidance.
Thanks in advance for your response!
Ted
--
Ted Berei, Pharm.D, MBA
PGY2 Cardiology Resident
Abbott Northwestern Hospital, Minneapolis Heart Institute
Office: 612-863-4508| Fax: 612-863-1309|Pager: 612-654-6830
800 East 28th Street | Minneapolis, MN 55407
Email: Theodore.Berei@allina.com